Sir,

The pharmacokinetic and pharmacodynamic results of liberated propofol published by Shah *et al*. could be inaccurate.\[[@ref1]\] They have mentioned in their article that they would carry out studies using appropriate assay methods to assess the same and find the degree of error within a period of 12 months. They have not been able to publish the new data and six previously published articles have been retracted.\[[@ref1]\] The assay inaccuracy is limited to propofol kinetics only, and therefore, previously published fospropofol kinetics are unaffected.\[[@ref2]\]

Time to achieve Cmax of liberated propofol at 12 and 8 min, the volume of distribution of liberated propofol 5.8 l/kg, and the mean terminal phase half life of 2.06 ± 0.77 h for propofol, described in pharmacokinetics in our article,\[[@ref3]\] may be inaccurate. Three references (Schywalsky *et al*.,\[[@ref4]\] Fechner *et al*.,\[[@ref5]\] and Gibiansky *et al*.\[[@ref6]\] ) in our review article\[[@ref3]\] have been retracted. Pharmacokinetic data of liberated propofol have been quoted by us from Gibiansky *et al* only . We wish to bring to your notice that US FDA approval label for fospropofol as on 21-01-2010, which was accessed by the authors on 17-08-2010 and 30-09-2011, about the pharmacokinetics of liberated propofol has not changed till date.\[[@ref7]\]
